Major Precious Metals Completes Skaergaard Site Visit
VANCOUVER, British Columbia, Sept. 21, 2020 (GLOBE NEWSWIRE) — Major Precious Metals Corp. (“Major Precious Metals” or the “Company”) (CSE:SIZE […]
Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). […]
Victory Square Health Provides a Progress Update on its Covid-19 Test
VANCOUVER, British Columbia, Sept. 20, 2020 (GLOBE NEWSWIRE) — Victory Square Health Inc. (“VS Health” or the “Company“) – a […]
iCAD Responds to CMS’ Finalized Radiation Oncology Alternative Payment Model
NASHUA, N.H., Sept. 20, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer […]
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibitionRecommended Phase 2 dose […]
Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology
― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic […]
RETRANSMISSION – DISPONIBILITÉ POUR LES MÉDIAS : Des agents de la Police du CN seront disponibles pour donner des entrevues pendant la Semaine de la sécurité ferroviaire 2020
MONTRÉAL, 20 sept. 2020 (GLOBE NEWSWIRE) — Le CN (TSX : CNR) (NYSE : CNI) offre aux médias la possibilité de s’entretenir […]
RETRANSMISSION – MEDIA AVAILABILITY: CN Police officers available for media interviews during Rail Safety Week
MONTREAL, Sept. 20, 2020 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) is offering members of the media the opportunity […]
MEDIA AVAILABILITY: CN Police officers available for media interviews during Rail Safety Week
HOMEWOOD, Ill., Sept. 19, 2020 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) is offering members of the media the […]
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic […]
